Research Focus Areas
Custom Synthesis of Metal/Porous Nanoparticles
Nanotoxicology
Biomedical Image Contrast Agents
Precision Nanoprobes
Molecular Nanotechnology
Custom Synthesis of Metal/Porous Nanoparticles
Standardized synthesis of Gold nanoparticles (nanoclusters, 5 nm, 10 nm, 16 nm) Silver nanoparticles (nanoclusters, 10 nm, 40 nm, 95 nm) Iron oxide nanoparticles (10 nm) Gadolinium oxide (5 nm, 10 nm) Hafnium oxide (5 nm, 10 nm) Microporous silica particles (15 nm, 50 nm, 100 nm, 400 nm) Other nanoparticles currently being optimized include …
Nanotoxicology
Nanotoxicity assessment is an integral part of designing biomedical probes. In vitro toxicity of nanoparticles is assessed using murine (L929) and human cell lines (HUVEC, RAW246.7). In vivo toxicity was assessed in zebrafish models, and in vivo biodistribution/blood pool kinetics was assessed in athymic and euthymic mouse models. Representative Publications …
Biomedical Image Contrast Agents
Scaled up the synthesis of nanoparticle contrast agents. I specialize in the synthesis of long emission lifetime, fluorescent and photoluminescent nanoparticles. This is achieved by modifying Au cores with fluorophore embedded shells or Au nanoclusters with tunable photoluminescence. Fluorescent silica particles with sizes ranging from 15 nm to 400 nm are also available. Such probes …
Precision Nanoprobes
Antibody-drug conjugates are emerging as a frontrunner in precision targeted therapeutics. However, this capability is still beyond the ability of most academic laboratories. The primary reason for this is the need to identify a precise binding site on the constant region of the antibody (Fc) for the drug molecule to be conjugated, while not affecting …
Molecular Nanotechnology
This is the current focus of my research. Utilizing anisotropic and hybrid nanoparticle architectures to introduce directionality in motion, precisely orienting targeting molecules and directed exertion of force by nanosystems. Anisotropic nanoparticles can be Janus hybrids or non-spherical nanoparticles and include rods, plates, prisms, and core-shells. This will lay the basis for nanomotors and nanomachines …
Military Health Sciences Research Symposium 2024. (Aug 26-29, 2024, Kissimmee FL)
Dr. Nallathamby presented on his abiotic biomimicking antibacterial Nanoparticles, and how they were successfully tested against A. baumannii BA1605 S.aureus USA300, P.aeruginosa FRD1, K. pneumoniae, C.striatum, E. faecalis, and S. pyogenes. We saw little to no evolution of resistance at doses above the MIC. Additionally, we observed what looks like inflammation-free wound healing in mouse and rat models. The wound size stabilizes as soon as the formulation is …
Sustained and Controlled Antibiotics Release for Prolonged Antibacterial Action Against MRSA, and Pseudomonas aeruginosa
Congratulations to REUs Argerie Guevara (NURF’21), and Kevin Armknecht (NURF’23) and Carlie Kudary (#BIPH) on the prolonged antibacterial action formulation of standard antibiotics to tackle MRSA and P.aeruginosa. More to come this year. #AMR #GOIRISH https://doi.org/10.1093/milmed/usae079
NIH Funding Opportunities
- Notice of Special Interest (NOSI): Accelerating Malaria Vaccine and Monoclonal Antibody Discovery November 20, 2024Notice NOT-AI-24-072 from the NIH Guide for Grants and Contracts
- Information and Practice Needs Relevant to Late Talking Children (R21 Clinical Trial Not Allowed) November 20, 2024Funding Opportunity PAR-25-217 from the NIH Guide for Grants and Contracts. The National Institutes of Health (NIH) Tackling Acquisition of Language in Kids (TALK) initiative seeks to support activities to better understand early language learning and delay. NIH TALK invites applications for research projects that aim to better understand the information and practice needs of […]
- Leveraging Extant Data to Understand Developmental Trajectories of Late Talking Children (R21 Clinical Trial Not Allowed) November 20, 2024Funding Opportunity PAR-25-220 from the NIH Guide for Grants and Contracts. The purpose of this notice of funding opportunity (NOFO) is to support research projects that aim to further understanding of the developmental trajectories of late talking children by leveraging existing data and creating open and shared data resources to aid in identifying patterns and […]
- Chemical Countermeasures Research Program (CCRP) Initiative: Basic Research on The Deleterious Effects of Acute Exposure to Ultra-Potent Synthetic (UPS) Opioids (R01 Clinical Trial Not Allowed) November 20, 2024Funding Opportunity RFA-DA-26-034 from the NIH Guide for Grants and Contracts. This notice of funding opportunity (NOFO) will support research towards understanding and mitigating the deleterious effects of acute exposure to Ultra-Potent Synthetic (UPS) opioids (e.g., fentanyl, carfentanil, nitazenes) and their combinations (fentanyl and xylazine). This NOFO will also support research on the persistent and/or […]
- Occupational Safety and Health Training Project Grants [T03] November 20, 2024Funding Opportunity RFA-OH-25-003 from the NIH Guide for Grants and Contracts. The purpose of this announcement is to invite grant applications for Training Project Grants that are focused on occupational safety and health training.
- Notice of Special Interest (NOSI): Leveraging Microbial Exposure for Improving Mouse Models of Human Immunity November 20, 2024Notice NOT-AI-24-078 from the NIH Guide for Grants and Contracts
- Notice of Early Expiration of "Notice of Special Interest (NOSI): Leveraging Microbial Exposure for Improving Mouse Models of Human Immunity", NOT-AI-21-072 November 20, 2024Notice NOT-AI-25-001 from the NIH Guide for Grants and Contracts
- NCI Pathway to Independence Award (K99/R00 Clinical Trial Not Allowed) November 20, 2024Funding Opportunity PAR-25-135 from the NIH Guide for Grants and Contracts. The purpose of the NCI Pathway to Independence Award (K99/R00) program is to facilitate a timely transition of talented postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide […]
- Notice of Early Expiration of "Notice of Special Interest (NOSI): Accelerating Malaria Vaccine Discovery", NOT-AI-22-014 November 20, 2024Notice NOT-AI-24-086 from the NIH Guide for Grants and Contracts
- Notice of Participation of OBSSR in RFA-MH-26-140 "BRAIN Initiative: Brain Behavior Quantification and Synchronization- Next Generation Sensor Technology Development (U01 Clinical Trial Optional)" November 20, 2024Notice NOT-OD-25-034 from the NIH Guide for Grants and Contracts
Recent Comments